Patents by Inventor Adolfo Prandi

Adolfo Prandi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oxalamido-substituted tricyclic inhibitors of hepatitis b virus
    Patent number: 12465590
    Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.
    Type: Grant
    Filed: May 25, 2020
    Date of Patent: November 11, 2025
    Assignees: OSPEDALE SAN RAFFAELE S.R.L., IRBM S.P.A., ISTITUTO NAZIONALE DI GENETICA MOLECOLARE—INGM
    Inventors: Raffaele De Francesco, Lorena Donnici, Luca Guidotti, Matteo Iannacone, Romano Di Fabio, Vincenzo Summa, Adolfo Prandi, Pietro Randazzo, Leda Ivanova Bencheva, Marilenia De Matteo, Luca Ferrante, Davide Gornati, Alessandro Grillo
  • Spirocyclic inhibitors of hepatitis B virus
    Patent number: 12404284
    Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: September 2, 2025
    Assignees: Ospedale San Raffaele S.r.l., Istituto Nazionale Genetica Molecolare—INGM
    Inventors: Romano Di Fabio, Vincenzo Summa, Leda Ivanova Bencheva, Raffaele De Francesco, Lorena Donnici, Luca Guidotti, Matteo Iannacone, Adolfo Prandi, Marilenia De Matteo, Pietro Randazzo
  • SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS
    Publication number: 20230151027
    Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.
    Type: Application
    Filed: February 9, 2021
    Publication date: May 18, 2023
    Applicants: Ospedale San Raffaele S.r.l., Istituto Nazionale Genetica Molecolare - INGM
    Inventors: Romano DI FABIO, Vincenzo SUMMA, Leda Ivanova BENCHEVA, Raffaele DE FRANCESCO, Lorena DONNICI, Luca GUIDOTTI, Matteo IANNACONE, Adolfo PRANDI, Marilenia DE MATTEO, Pietro RANDAZZO
  • INHIBITORS OF HEPATITIS B VIRUS
    Publication number: 20230076319
    Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.
    Type: Application
    Filed: October 4, 2022
    Publication date: March 9, 2023
    Inventors: Raffaele DE FRANCESCO, Lorena DONNICI, Luca GUIDOTTI, Matteo IANNACONE, Romano DI FABIO, Vincenzo SUMMA, Adolfo PRANDI, Pietro RANDAZZO, Davide GORNATI, Alessandro GRILLO, Luca FERRANTE, Leda Ivanova BENCHEVA, Marilenia DE MATTEO, Marco FERRARA
  • Tricyclic inhibitors of Hepatitis B virus
    Patent number: 11504382
    Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: November 22, 2022
    Assignee: Antios Therapeutics, Inc.
    Inventors: Raffaele De Francesco, Lorena Donnici, Luca Guidotti, Matteo Iannacone, Romano Di Fabio, Vincenzo Summa, Adolfo Prandi, Pietro Randazzo, Davide Gornati, Alessandro Grillo, Luca Ferrante, Leda Ivanova Bencheva, Marilenia De Matteo, Marco Ferrara
  • OXALAMIDO-SUBSTITUTED TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS
    Publication number: 20220241241
    Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.
    Type: Application
    Filed: May 25, 2020
    Publication date: August 4, 2022
    Applicants: ISTITUTO NAZIONALE DI GENETICA MOLECOLARE - INGM, OSPEDALE SAN RAFFAELE S.R.L., IRBM S.P.A.
    Inventors: Raffaele DE FRANCESCO, Lorena DONNICI, Luca GUIDOTTI, Matteo IANNACONE, Romano DI FABIO, Vincenzo SUMMA, Adolfo PRANDI, Pietro RANDAZZO, Leda IVANOVA BENCHEVA, Marilenia DE MATTEO, Luca FERRANTE, Davide GORNATI, Alessandro GRILLO
  • TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS
    Publication number: 20220110943
    Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.
    Type: Application
    Filed: August 9, 2019
    Publication date: April 14, 2022
    Applicants: OSPEDALE SAN RAFFAELE S.R.L., IRBM S.P.A., PROMIDIS S.R.L., ISTITUTO NAZIONALE DI GENETICA MOLECOLARE - INGM
    Inventors: Raffaele DE FRANCESCO, Lorena DONNICI, Luca GUIDOTTI, Matteo IANNACONE, Romano DI FABIO, Vincenzo SUMMA, Adolfo PRANDI, Pietro RANDAZZO, Davide GORNATI, Alessandro GRILLO, Luca FERRANTE, Leda Ivanova BENCHEVA, Marilenia DE MATTEO, Marco FERRARA
  • INHIBITORS OF HEPATITIS B VIRUS
    Publication number: 20210276967
    Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing said compounds.
    Type: Application
    Filed: July 19, 2019
    Publication date: September 9, 2021
    Applicants: OSPEDALE SAN RAFFAELE S.R.L., IRBM S.P.A., PROMIDIS S.R.L., ISTITUTO NAZIONALE DI GENETICA MOLECOLARE - INGM
    Inventors: Raffaele DE FRANCESCO, Adolfo PRANDI, Pietro RANDAZZO, Lorena DONNICI, Luca GUIDOTTI, Matteo IANNACONE, Romano DI FABIO, Vincenzo SUMMA, Leda Ivanova BENCHEVA, Marilenia DE MATTEO, Luca FERRANTE
  • Process for preparing intermediates for the synthesis of optically active beta-amino alcohols by enzymatic reduction and novel synthesis intermediates
    Patent number: 11053227
    Abstract: Subject-matter of the present invention is a process for preparing intermediates for the synthesis of optically active beta-amino alcohols by enzymatic reduction of the corresponding beta-amino ketones. Subject-matter of the invention are also said novel synthesis intermediates and the use thereof in the preparation of active pharmaceutical ingredients, among which vilanterol and the salts thereof.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: July 6, 2021
    Assignee: OLON S.P.A.
    Inventors: Corrado Colli, Giorgio Bertolini, Mara Sada, Faris Garis, Filippo Nisic, Aldo Bianchi, Cinzia Biaggi, Romano Di Fabio, Silvano Ronzoni, Stefania Bertuolo, Adolfo Prandi, Stefano Maiorana
  • PROCESS FOR PREPARING INTERMEDIATES FOR THE SYNTHESIS OF OPTICALLY ACTIVE BETA-AMINO ALCOHOLS BY ENZYMATIC REDUCTION AND NOVEL SYNTHESIS INTERMEDIATES
    Publication number: 20200385366
    Abstract: Subject-matter of the present invention is a process for preparing intermediates for the synthesis of optically active beta-amino alcohols by enzymatic reduction of the corresponding beta-amino ketones. Subject-matter of the invention are also said novel synthesis intermediates and the use thereof in the preparation of active pharmaceutical ingredients, among which vilanterol and the salts thereof.
    Type: Application
    Filed: December 19, 2018
    Publication date: December 10, 2020
    Inventors: Corrado COLLI, Giorgio BERTOLINI, Mara SADA, Faris GARIS, Filippo NISIC, Aldo BIANCHI, Cinzia BIAGGI, Romano DI FABIO, Silvano RONZONI, Stefania BERTUOLO, Adolfo PRANDI, Stefano MAIORANA
  • Substituted N-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and N-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives P2X7 receptor antagonists
    Patent number: 10669267
    Abstract: The present invention relates to novel substituted phenoxy- and benzyloxy-piperidine compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: June 2, 2020
    Assignee: Axxam S.P.A.
    Inventors: Paolo Pevarello, Adolfo Prandi
  • SUBSTITUTED N-[2-(4-PHENOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE AND N-[2-(4-BENZYLOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE DERIVATIVES P2X7 RECEPTOR ANTAGONISTS
    Publication number: 20190194180
    Abstract: The present invention relates to novel substituted phenoxy- and benzyloxy-piperidine compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.
    Type: Application
    Filed: August 9, 2017
    Publication date: June 27, 2019
    Applicant: Axxam S.P.A.
    Inventors: Paolo Pevarello, Adolfo Prandi
  • Substituted thiazole or oxazole P2X7 receptor antagonists
    Patent number: 10167281
    Abstract: The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties: The compounds are useful in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.
    Type: Grant
    Filed: June 18, 2017
    Date of Patent: January 1, 2019
    Assignee: Axxam S.P.A.
    Inventors: Paolo Pevarello, Stefan Lohmer, Chiara Llberati, Pierfausto Seneci, Cristina Pesenti, Adolfo Prandi
  • SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS
    Publication number: 20170283409
    Abstract: The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties: The compounds are useful in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.
    Type: Application
    Filed: June 18, 2017
    Publication date: October 5, 2017
    Applicant: Axxam S.P.A.
    Inventors: Paolo Pevarello, Stefan Lohmer, Chiara LIberati, Pierfausto Seneci, Cristina Pesenti, Adolfo Prandi
  • Substituted thiazole or oxazole P2X7 receptor antagonists
    Patent number: 9718812
    Abstract: The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties. The compounds are useful in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: August 1, 2017
    Assignee: Axxam S.P.A.
    Inventors: Paolo Pevarello, Stefan Lohmer, Chiara Llberati, Pierfausto Seneci, Cristina Pesenti, Adolfo Prandi
  • SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS
    Publication number: 20170008883
    Abstract: The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties. The compounds are useful in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.
    Type: Application
    Filed: February 4, 2015
    Publication date: January 12, 2017
    Applicant: Axxam S.P.A.
    Inventors: Paolo Pevarello, Stefan Lohmer, Chiara LIberati, Pierfausto Seneci, Cristina Pesenti, Adolfo Prandi
  • Azabicyclo [3.1.0] hexylphenyl derivatives as modulators of dopamine D3 receptors
    Patent number: 7776904
    Abstract: The present invention relates to novel compounds of formula (IA) or a salt thereof: wherein: A is attached to the phenyl group at the meta position or the para position relative to the cyclopropyl group, and is selected from the group consisting of: —SO2NR5—, —SO2CR2R3—, —CR2R3SO2— and —NR5SO2—; R1 is hydrogen, C1-6alkyl, haloC1-6alkyl or C2-6alkylene; R2 and R3 are independently hydrogen or C1-6alkyl; R4 is hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy or haloC1-6alkoxy; R5 is hydrogen, C1-6alkyl, or a phenyl optionally substituted by R4; and R6 is hydrogen, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy or haloC1-6alkoxy; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat substance related disorders, as antipsychotic agents premature ejaculation or cognition impairment.
    Type: Grant
    Filed: August 18, 2006
    Date of Patent: August 17, 2010
    Assignee: Glaxo Group Limited
    Inventors: Gabriella Gentile, Dieter Hamprecht, Fabrizio Micheli, Adolfo Prandi, Silvia Terreni
  • AZABICYCLO [3.1.0] HEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS
    Publication number: 20090030062
    Abstract: The present invention relates to novel compounds of formula (IA) or a salt thereof: wherein: A is attached to the phenyl group at the meta position or the para position relative to the cyclopropyl group, and is selected from the group consisting of: —SO2NR5—, —SO2CR2R3—, —CR2R3SO2— and —NR5SO2—; R1 is hydrogen, C1-6alkyl, haloC1-6alkyl or C2-6alkylene; R2 and R3 are independently hydrogen or C1-6alkyl; R4 is hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy or haloC1-6alkoxy; R5 is hydrogen, C1-6alkyl, or a phenyl optionally substituted by R4; and R6 is hydrogen, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy or haloC1-6alkoxy; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat substance related disorders, as antipsychotic agents premature ejaculation or cognition impairment.
    Type: Application
    Filed: August 18, 2006
    Publication date: January 29, 2009
    Inventors: Gabriella Gentile, Dieter Hamprecht, Fabrizio Micheli, Adolfo Prandi, Silvia Terreni